Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
Open Access
- 1 January 2020
- journal article
- editorial
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 38 (3) , 254-255
Abstract
Mondaini N. World J Mens Health. 2020 Jan;38:e28. https://doi.org/10.5534/wjmh.200089Keywords
This publication has 7 references indexed in Scilit:
- Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in PointJMIR Public Health and Surveillance, 2020
- Endothelial cell infection and endotheliitis in COVID-19The Lancet, 2020
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysisInternational Journal of Infectious Diseases, 2020
- Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesisCritical Care and Resuscitation, 2020
- Tadalafil: 15 years' journey in male erectile dysfunction and beyondDrug Development Research, 2018
- A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2010